Loading the company…
Loading the company…
㈜나라바이오
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-09 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Jeonbuk, founded in 2018. Industry: Chemicals & Materials. Revenue for 2025 was ₩3.0bn. It has 7 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Disclaimer of opinion”.
Loading…
Latest filing 2021-02-23 · latest registration 2023-01-10 · newest first
본 발명은 본 발명은 무독성 유황(NTS) 또는 메틸설포닐메탄(MSM)의 염증성 질환 예방, 치료 또는 개선 용도에 관한 것으로, 상기 NTS 또는 MSM는 고농도의 글루코스로 인해 유도된, TLR2 및 TLR4 단백질 발현 억제, 활성산소종 생성 억제를 통한 NF-κB 활성을 억제, IL-1β, IL-6 및 TNF-α와 같은 전 염증성 사이토카인 발현 억제 효과가 있으므로 고농도 글루코스로 인한 염증성 질환의 예방, 치료 또는 개선 용도로 유용하게 이용될 수 있다.
본 발명은 제독유황을 스트렙토마이세스균이 주종인 방선균으로 이루어진 유용 미생물군(EM: Effective Microorganism)에 의해 발효시킨 발효 제독유황을 유효성분으로 포함하는 성장 촉진용 조성물에 관한 것이다. 이에 의하여, 본 발명의 조성물은 Jak2/STAT5b/IGF-1 신호전달 경로의 발현을 상향 조절함으로써 성장호르몬 신호전달 능력을 증진시켜 성장을 촉진할 수 있다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 4.8 | 3.0 |
| Cost of sales | 4.3 | 2.3 |
| Gross profit (loss) | 0.5 | 0.7 |
| Selling, general and administrative expenses | 2.5 | 1.5 |
| Operating income (loss) | (2.0) | (0.8) |
| Non-operating income | 0.2 | 1.3 |
| Other gains | 0.1 | 0.3 |
| Finance income | 0.0 | 0.0 |
| Other | 0.0 | 0.9 |
| Non-operating expenses | 4.6 | 1.0 |
| Other losses | — | 0.0 |
| Finance costs | 0.9 | 0.9 |
| Other | 3.8 | 0.1 |
| Profit (loss) before tax | (6.4) | (0.5) |
| Net income (loss) | (6.4) | (0.5) |
Revenue ₩3bn, down 37.0% YoY.
Operating margin -27.5% (prior -41.4%).
Net income ₩-0.5bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.